$2.51
arrow_drop_down10.35%Key Stats | |
---|---|
Open | $2.76 |
Prev. Close | $2.80 |
EPS | 1,232.39 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $2.96M |
LOW | HIGH | |
---|---|---|
Day Range | 2.50 | 2.76 |
52 Week Range | 0.50 | 7.98 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | 1,232.39 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update